The $100 million consent decree that Abbott Diagnostics signed with the Food and Drug Administration in early November took many in the diagnostics industry by surprise and has left them shaken.
As the world's largest provider of immunoassay systems and tests, with a market share that seems unassailable, Abbott Laboratories Inc. 's diagnostics business has fared comparatively well during a period of industry turmoil. But the $100 million consent decree it signed in early November with the Food and Drug Administration has left the diagnostics industry shaken.
As most people in diagnostics know by now, the FDA accuses Abbott of failing to comply with Good Manufacturing Practices...
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
